Izvorni znanstveni članak

Clinical Value of Serum HMGB1 Levels in Early Detection of Recurrent Squamous Cell Carcinoma of Uterine Cervix: Comparison with Serum SCCA, CYFRA21-1, and CEA Levels

Xiugui Sheng ; Department of Gynecologic Oncology, Shandong Cancer Hospital&Institute, Jinan Shandong Province, People's Republic of China
Xuelian Du ; Department of Gynecologic Oncology, Shandong Cancer Hospital&Institute, Jinan Shandong Province, People's Republic of China
Xiaoling Zhang ; Department of Gynecologic Oncology, Shandong Cancer Hospital&Institute, Jinan Shandong Province, People's Republic of China
Dapeng Li ; Department of Gynecologic Oncology, Shandong Cancer Hospital&Institute, Jinan Shandong Province, People's Republic of China
Chunhua Lu ; Department of Gynecologic Oncology, Shandong Cancer Hospital&Institute, Jinan Shandong Province, People's Republic of China
Qinshui Li ; Department of Gynecologic Oncology, Shandong Cancer Hospital&Institute, Jinan Shandong Province, People's Republic of China
Zhifang Ma ; Department of Gynecologic Oncology, Shandong Cancer Hospital&Institute, Jinan Shandong Province, People's Republic of China
Quqing Song ; Department of Gynecologic Oncology, Shandong Cancer Hospital&Institute, Jinan Shandong Province, People's Republic of China
Cong Wang ; Department of Gynecologic Oncology, Shandong Cancer Hospital&Institute, Jinan Shandong Province, People's Republic of China

Sažetak

Aim To evaluate the clinical value of serum high mobility
group box chromosomal protein 1 (HMGB1) levels in making
the early diagnosis of recurrent cervical squamous cell carcinomas
(CSCC) and compare it with the value of serum squamous
cell carcinoma antigen (SCCA), cytokeratin fragment
(CYFRA) 21-1, and carcinoembryonic antigen (CEA) levels.
Methods Immunohistochemical staining of tissue from 64
patients with recurrent CSCCs, 72 patients with non-recurrent
carcinoma, and 28 healthy participants was performed to determine
the expression of HMGB1 protein. The serum levels
of the 4 markers in 112 patients with recurrent CSCC, 174 patients
with non-recurrent disease, and 128 healthy participants
were measured by enzyme-linked immunosorbent assay. The
receiver operating characteristic (ROC) curves were constructed
and the area under the curve (AUC) was calculated.
Results Higher immunostaining score was found in recurrent
CSCC tissue sections than in non-recurrent CSCC sections.
Serum HMGB1 levels in patients with recurrent CSCC
were significantly higher than in patients with non-recurrent
disease and healthy controls. The AUC of HMGB1, SCCA, CYFRA21-
1, and CEA was 0.816, 0.768, 0.703, and 0.625, respectively.
HMGB1 had the best specificity and positive likelihood
ratio (78.0% and 3.25, respectively), whereas SCCA had the
best sensitivity and negative likelihood ratio (76.3% and 0.34,
respectively). Parallel combined measurements increased the
diagnostic sensitivity and serial combination increased the
specificity. High serum HMGB1 levels were inversely correlated
with disease-free survival (P = 0.009, Pearson χ2 test) and
overall survival (P = 0.018).
Conclusion HMGB1 was overexpressed in recurrent CSCCs.
Serum HMGB1 level could be a useful and specific marker for
evaluating the disease recurrence and predicting prognosis
in patients with CSCC. Serial combined measurements of serum
HMGB1, SCCA, and CYFRA21-1 increased the diagnostic
specificity, and parallel combined testing increased the diagnostic
sensitivity.

Ključne riječi

Recurrent Cervical Carcinoma; HMGB1; SCC; CYFRA21-1; CEA

Hrčak ID:

47866

URI

https://hrcak.srce.hr/47866

Datum izdavanja:

15.10.2009.

Posjeta: 1.853 *